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Multidrug-resistant tuberculosis (MDR-TB) threatens global TB control. The lengthy treatment includes one of the injectable
drugs kanamycin, amikacin, and capreomycin, usually for the first 6 months. These drugs have potentially serious toxicities, and
when given as intramuscular injections, dosing can be painful. Advances in particulate drug delivery have led to the formulation
of capreomycin as the first antituberculosis drug available as a microparticle dry powder for inhalation and clinical study. Deliv-
ery by aerosol may result in successful treatment with lower doses. Here we report a phase I, single-dose, dose-escalating study
aimed at demonstrating safety and tolerability in healthy subjects and measuring pharmacokinetic (PK) parameters. Twenty
healthy adults (n  5 per group) were recruited to self-administer a single dose of inhaled dry powder capreomycin (25-mg, 75-
mg, 150-mg, or 300-mg nominal dose) using a simple, handheld delivery device. Inhalations were well tolerated by all subjects.
The most common adverse event was mild to moderate transient cough, in five subjects. There were no changes in lung function,
audiometry, or laboratory parameters. Capreomycin was rapidly absorbed after inhalation. Systemic concentrations were de-
tected in each dose group within 20 min. Peak and mean plasma concentrations of capreomycin were dose proportional. Serum
concentrations exceeded 2 g/ml (MIC for Mycobacterium tuberculosis) following the highest dose; the half-life (t1/2) was 4.8 
1.0 h. A novel inhaled microparticle dry powder formulation of capreomycin was well tolerated. A single 300-mg dose rapidly
achieved serum drug concentrations above the MIC for Mycobacterium tuberculosis, suggesting the potential of inhaled therapy
as part of an MDR-TB treatment regimen.
Multidrug-resistant tuberculosis (MDR-TB) is difficult totreat and readily spread and threatens global tuberculosis
control, especially where HIV coinfection is common. According
to the WHO, an estimated 440,000 new cases of MDR-TB occur
each year (1, 2), but only a small fraction are receiving quality-
assured treatment (1). In most public health treatment programs,
18 to 24 months of therapy with four or more second-line drugs
are required. Second-line drugs are less efficacious, more toxic,
and associated with treatment success rates of only 40 to 80% (1,
3–6). According to current WHO MDR-TB treatment guidelines,
at least one injectable antibiotic (kanamycin, amikacin, or capreo-
mycin) is an essential part of the 6-month intensive phase of treat-
ment. These 3- to 7-times-per-week injections are painful for pa-
tients, especially for children and those with little muscle mass.
Injections require skilled health care staff and place them at risk of
needle stick injuries and infections (3). Treatment with injectable
drugs is associated with systemic toxicity, including nephrotoxic-
ity, which is typically mild and reversible, and ototoxicity, which
can be significant and irreversible. Dosing must also be adjusted in
individuals with preexisting renal insufficiency. Lastly, injectable
drugs require a cold chain for storage and sterile conditions for
reconstitution.
Despite these drawbacks, injectable drugs remain an important
part of the treatment of MDR-TB because of their in vitro activity
against actively replicating M. tuberculosis, their ability to inhibit
the development of drug resistance when used in combination
with other drugs (7), and the lack of alternative drugs to replace
them. There are two important classes of injectable drugs: the
aminoglycosides (e.g., amikacin and kanamycin) and the poly-
peptide agent capreomycin. Capreomycin has also been shown to
have activity against nonreplicating forms of M. tuberculosis (8).
The parenteral administration of aminoglycosides in humans,
however, is associated with relatively low lung concentrations of
these antibiotics, and high peak serum concentrations (Cmax) are
needed to obtain microbiologically active concentrations in the
alveoli, in the pulmonary interstitium, and intracellularly within
macrophages, the most common sites of M. tuberculosis infection.
In the few published clinical studies specifically evaluating alveo-
lar lining fluid concentrations of aminoglycosides after systemic
administration, alveolar concentrations ranged from 32% to 50%
of the peak systemic concentration (9–11). Furthermore, preclin-
ical studies of capreomycin pharmacokinetics in mice have shown
that parenteral doses penetrate poorly into the lung (12). Since
clinical effectiveness of the aminoglycosides and capreomycin is
closely correlated with the ratio of Cmax to MIC, based on in vitro
and in vivo studies with Gram-negative bacteria and with M. tu-
berculosis (13–15), one of the major challenges in TB chemother-
apy is the ability to achieve both adequate lung compartment-
specific Cmax and systemic Cmax (for extrapulmonary sites of
infection) while limiting or avoiding systemic toxicity.
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Inhaled drug delivery offers the potential to achieve high con-
centrations of pharmacologic agents in the lungs while producing
adequate systemic concentrations through alveolar-capillary ab-
sorption to treat extrapulmonary sites of infection. It also offers
the potential of reduced manufacturing costs and administration
of lower doses. Inhaled nebulized antimicrobials are used in the
treatment of pulmonary infections (both viral and bacterial) in
various patient populations, such as in individuals with cystic fi-
brosis and bronchiectasis and for antimicrobial prophylaxis (fun-
gal and bacterial) of the lung following pulmonary transplanta-
tion (16–18). An important requirement in the management of
tuberculosis, especially for HIV-infected individuals, is to achieve
therapeutic systemic drug concentrations in order to treat ex-
trapulmonary foci of infection. Fortunately, the science of drug
delivery continues to evolve, converting parenteral, oral, or
nebulized drugs into chemically or physically modified inhaled
formulations that enhance delivery to specific distal lung tissue
compartments, with or without systemic absorption, as required
(19, 20). Inhaled dry powder formulations of drugs are particu-
larly attractive because they may help avoid the requirements for
electricity, cold chains for storage, and materials for reconstitu-
tion needed to administer nebulized formulations of drugs, espe-
cially in resource-limited settings. One such unique, dry powder,
microparticle formulation of capreomycin exhibited good aero-
solization properties, physical-chemical stability, efficient lung
deposition, and absorption in preclinical testing (21).
Capreomycin sulfate is a polypeptide antibiotic indicated for
infections caused by drug-resistant strains of M. tuberculosis.
Capreomycin is administered intramuscularly (i.m.) or intrave-
nously (i.v.) at a usual dose of 15 to 20 mg/kg of body weight/day
for at least 6 months, but it may be needed for as long as 2 years if
tolerated. Capreomycin is currently used in combination with at
least three or four other antituberculosis agents to which the pa-
tient’s strain is susceptible (22). In two clinical studies of 10 pa-
tients each, peak serum concentrations following administration
of 1 g of capreomycin given intramuscularly reached 28 and 32
g/ml, respectively (range, 20 to 47 g/ml), 1 to 2 h after admin-
istration, and by 24 h postdose, concentrations were very low (Eli
Lilly, unpublished data). Among 722 patients treated with paren-
terally administered capreomycin, 3% developed clinical hearing
loss (FDA label) (23).
Preceding the current clinical study, preclinical toxicological
studies of the inhaled dry powder formulation in rats and dogs
given the drug for 14 days and monitored for up to 14 days post-
exposure showed mild, reversible, dose-dependent irritation of
the respiratory tract histopathologically and helped establish a no-
adverse-effect level (NOAEL) of 7 mg/kg in the dog model (un-
published data). In this first-in-human study, we used capreomy-
cin in inhaled doses ranging from doses 22-fold lower than the
NOAEL in dogs (for the 25-mg group) to 1.8-fold lower than the
NOAEL in dogs (for the 300-mg group). Preclinical pharmacoki-
netic (PK) studies of inhaled capreomycin in the guinea pig have
shown efficient drug absorption from the lung into blood and a
linear terminal phase of the plasma concentration-time curve
(24). Together, these preclinical data suggested that the inhalable
microparticle formulation of capreomycin used in this clinical
study could safely produce both pulmonary and systemic concen-
trations above the MIC for M. tuberculosis. The objectives of this
phase I study were therefore to determine the safety, tolerability,
and systemic pharmacokinetics of inhaled dry powder capreomy-
cin in healthy adult volunteers.
MATERIALS AND METHODS
Study design. We conducted a phase I clinical study among 20 healthy
adult volunteers. Inclusion criteria included an age of 18 to 65 years; no
history of current or recent (within the past 6 months) tobacco use; no
current medication usage; normal renal, hematologic, and liver tests; and
FEV1 (forced expiratory volume in 1 second), FVC (forced vital capacity),
and DLCO (diffusing capacity of the lung for carbon monoxide) greater
than or equal to the lower limit of the 95% confidence interval for the
predicted value for the subject based on age and height. Exclusion criteria
included pregnancy and current breastfeeding; receipt of capreomycin,
aminoglycosides, or any other investigational drug within the 30-day pe-
riod before study drug administration; or a history of intolerance of
capreomycin or aminoglycoside antibiotics. Additional exclusion criteria
included use of prescription medications (except hormonal contracep-
tion) in the 30-day period before study drug administration, use of non-
prescription medication within 7 days before study drug administration,
abnormalities on any screening examination or test, or history of asthma.
Baseline and 24-h-postdose (final) pulmonary function testing was
performed by using pulmonary function testing equipment (Morgan Sci-
entific, Haverhill, MA). At 1, 2, 3, 4, 6, 8, 12, 30, and 36 h postdose, a
handheld spirometer (KoKo Legend; nSpire Health) was used to measure
FEV1, FVC, and FEV1/FVC. Upon enrollment, subjects were sequentially
assigned to one of four escalating dosage groups (25 mg, 75 mg, 150 mg,
and 300 mg capreomycin; n  5 per group).
Each subject received a single dose of inhaled capreomycin according
to the dose group, which was self-administered by using a handheld in-
FIG 1 Handheld inhaler for self-administration of capreomycin. (Left) Inhaler in full view; (middle) inhaler opened, showing the chamber that holds the
capsule; (right) inhaler with capsule inserted.
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haler (Cyclohaler; Plastiape, Italy) (Fig. 1). Capsules (each containing 25
mg of capreomycin and 5 mg of the excipient L-leucine, at an 80:20 ratio)
were inserted sequentially into the handheld inhaler for self-administra-
tion. Capsules were punctured within the handheld inhaler to release the
drug prior to inhalation. Group 1 (25-mg dose) self-administered one
capsule, while group 4 (300-mg dose) self-administered 12 capsules.
Each subject underwent blood sampling for capreomycin pharmaco-
kinetic analysis at 13 time points: predose; 10, 20, 30, and 45 min postdose;
as well as 1, 2, 3, 4, 6, 8, 12, and 24 h postdose. Drug concentrations were
assayed by using a highly sensitive high-performance liquid chromatog-
raphy tandem mass spectrometry (HPLC-MS/MS) methodology. The
lower limit of quantitation of capreomycin in human plasma was 100
ng/ml, with an accuracy of 88.2%, and the linear range of quantitation was
100 to 5,000 ng/ml. The HPLC-MS/MS assay was validated by using vio-
mycin as an internal standard. In addition, subjects underwent blood
sampling, urinalysis, audiometry, and chest X ray (CXR) at 24 h postdose
for safety assessments. The study scheme is illustrated in Fig. 2.
Study drug formulation. Capreomycin inhalation powder was devel-
oped by using spray-drying technology (21) and manufactured and qual-
ity control released by using fully good manufacturing practices (GMP)-
compliant processes and facilities. For the 80:20 (capreomycin-leucine
excipient) dry powder formulation, prior work using scanning electron
microscopy demonstrated the mean geometric particle diameter (at a
pressure of 1 Pa) to be 3.69  1.68 m (21). Particles with lower capreo-
mycin content (e.g., 50 to 70 wt%) had higher mean geometric diameters
than the 80:20 particles (21). Mass mean aerodynamic diameters
(MMADs) of the 80:20 formulation were 4.74  0.07 m, as determined
by cumulative mass distribution curves of aerosol collections on cascade
impactors (21), suggesting some aggregation of particles, as has been ob-
served for dry powders (25). In vitro estimation of particle distribution
based on its size suggested that the 80:20 formulation would yield both
bronchial and alveolar deposition of drug. The study drug was stored at
2°C to 8°C (note that, with additional stability data, the product may now
be stored at controlled room temperature).
Statistical analyses. Clinical and demographic data on study subjects
are reported using summary measures. Pharmacokinetic data were also
summarized descriptively and stratified by dosing group by using SAS
version 8.2. The PK population consisted of all subjects who enrolled in
the study, received the full dose of study drug, and completed the study.
Subjects for whom select PK parameters could not be adequately charac-
terized (e.g., half-life [t1/2] was not reported, per internal standard oper-
ating procedures, if the adjusted r2 value was 0.75 and the time points
used in estimating the half-life spanned less than 1 half-life) were excluded
TABLE 1 Clinical characteristics of the study subjects
Clinical parametera Value
Male/female ratio 17:3
Mean age (yr) (range) 39.4 (18–59)
Mean wt (lb)  SD 174.5  38.4
Mean height (in.)  SD 69.3  3.8
Mean BMI (lb/in2)  SD 25.6  5.7
Mean FEV1 (baseline) (liters)  SD 4.04  0.78
Mean FVC (baseline) (liters)  SD 4.06  1.20
Mean FEV1/FVC ratio (baseline)  SD 0.78  0.09
Mean creatinine concn (baseline) (mg/dl)  SD 0.97  0.17
a BMI, body mass index.
FIG 2 Study flow chart/scheme. CXR, chest X ray; U/A, urinalysis; PK, pharmacokinetic.
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from the calculation of overall means and statistics for those select param-
eters. PK analyses were performed by using standard, noncompartmental
methods.
Human subject research approval. All research was approved by the
institutional review board of the Brigham and Women’s Hospital and was
conducted in accordance with good clinical practice and good laboratory
practice guidelines.
RESULTS
Subject characteristics. Twenty adult subjects were enrolled in
this study. Their characteristics are summarized in Table 1.
Pharmacokinetic data. Capreomycin was detectable in serum
samples within 20 min of inhalation in 17/20 (85%) subjects. In
three subjects, the initial detection of capreomycin occurred at
between 1 and 3 h postdose. These three subjects were all in the
25-mg (lowest) dose group. In the 25-mg dose group, the mean
area under the concentration-time curve from 0 h to the last mea-
surable concentration (AUC0 –t) was 969 h · ng/ml, while in the
300-mg dose group, the mean AUC0 –t was 19,959 h · ng/ml. The
mean Cmax values for each successive dose group were 169 ng/ml,
569 ng/ml, 972 ng/ml, and 2,315 ng/ml. The average times to
maximal concentration (Tmax) in each group were 2.4 h (25-mg
group), 2.1 h (75-mg group), 3.2 h (150-mg group), and 2.8 h
(300-mg group). The apparent t1/2 values were 4.2  1.1 h (75-mg
group), 4.4  1.3 h (150-mg group), and 4.8  1.0 h (300-mg
group). Table 2 summarizes these values.
The mean plasma drug concentrations versus time for each
dosage group are shown in Fig. 3. Superimposed upon Fig. 3 is an
MIC of 2 g/ml (or 2,000 ng/ml) for M. tuberculosis based on





(n  5 subjects)
3 (150-mg dose)
(n  5 subjects)
4 (300-mg dose)
(n  5 subjects)
AUC0–t (h · ng/ml)
Mean (no.) 969 (5) 3,555 (5) 7,019 (5) 19,959 (5)
Range (min, max) 51, 2,176 1,450, 5,274 1,761, 14,187 7,554, 35,855
Median 1,083 4,035 4,984 16,843
AUC0– (h · ng/ml)
Mean (no.) NR 5,683 (3) 9,333 (4) 22,425 (5)
Range (min, max) 4,785, 6,516 5,488,15,253 9,505, 37,194
Median 5,747 8,296 22,503
Cmax (ng/ml)
Mean (no.) 169 (5) 569 (5) 972 (5) 2,315 (5)
Range (min, max) 102, 250 218, 970 250, 1,947 939, 4,579
Median 178 513 786 2,105
Tmax (h)
Mean (no.) 2.4 (5) 2.1 (5) 3.2 (5) 2.8 (5)
Range (min, max) 2.0, 3.0 0.5, 4.0 1.0, 6.0 2.0, 3.0
Median 2.0 2.0 3.0 3.0
kel (1/h)
Mean (no.) NR 0.171 (3) 0.167 (4) 0.151 (5)
Range (min, max) 0.127, 0.206 0.111, 0.197 0.116, 0.214
Median 0.180 0.180 0.138
t1/2 (h)
Mean (no.) NR 4.2 (3) 4.4 (4) 4.8 (5)
Range (min, max) 3.4, 5.4 3.5, 6.3 3.2, 6.0
Median 3.9 3.8 5.0
CL/F (ml/min/kg)
Mean (no.) NR 3.13 (3) 4.57 (4) 3.46 (5)
Range (min, max) 2.99, 3.38 1.99, 7.17 1.61, 6.63
Median 3.02 4.55 2.37
V/F (liters/kg)
Mean (no.) NR 1.14 (3) 1.60 (4) 1.35 (5)
Range (min, max) 0.87, 1.42 1.06, 2.4 0.70, 2.65
Median 1.13 1.47 1.11
a AUC0 –t, area under the plasma concentration-time curve computed up to the last measurable concentration; AUC0 –, area under the plasma concentration-time curve from time
of dosing to infinity with extrapolation of the terminal phase; Cmax, peak drug concentration; Tmax, time to reach maximum plasma concentration; kel, terminal elimination rate
constant; t1/2, terminal elimination half-life; CL/F, apparent total body clearance uncorrected for fraction absorbed after extravascular administration; V/F, apparent volume of
distribution uncorrected for fraction absorbed based on the terminal elimination phase; NR, not calculated for reasons described in Materials and Methods.
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values reported in other studies (26). Both the maximal plasma
concentration (Cmax) and the AUC from 0 h to infinity (AUC0 –)
were dose proportional, as shown in Fig. 4.
Safety data. Inhalation of capreomycin was not associated with
alterations in clinical or laboratory parameters. Pulmonary func-
tion was unchanged postinhalation (Table 3). Renal function was
similarly unchanged after study drug administration. There were
no abnormalities in liver function tests; leukocyte, red blood cell,
or platelet counts; or urine sediment in any patients. Audiometry
was stable after dose administration.
Adverse events. There were no serious or severe adverse events
in this study. Several subjects experienced mild/moderate symp-
toms, the most common one being cough, occurring in 5 subjects.
Table 4 lists all the adverse events occurring in the study and their
relationship to the study drug. All adverse events were self-limited.
When coughing occurred, it started upon administration of study
drug and ended within 5 min of the last capsule that was actuated.
Coughing was reported by subjects as being mild/moderate.
DISCUSSION
In this study, we evaluated the safety and systemic pharmacoki-
netics of a novel dry powder formulation of the antituberculous
drug capreomycin, a polypeptide antibiotic that inhibits myco-
bacterial protein biosynthesis. After administration of a single
300-mg inhaled dose to healthy volunteers, systemic concentra-
tions were equal to or higher than reported MICs (2 g/ml) for M.
tuberculosis (26). From a safety and tolerability perspective, inha-
lation was easy to self-administer, well tolerated, and not associ-
ated with any significant alterations in pulmonary function, renal
function, or other clinical parameters.
Capreomycin elimination after single-dose inhalation showed
biphasic kinetics in all dose groups (Fig. 3). Absorption of the drug
through the lungs was rapid, as illustrated by detection of drug
within 20 min among all subjects receiving 75 mg or more of
capreomycin. The apparent t1/2 after inhalation ranged from 4.2 to
4.8 h. Maximal drug concentrations (Cmax) and the AUC were
dose proportional (Fig. 4), and since the highest nominal dose
used in this phase I study (300 mg) was below the conservative
estimate of the NOAEL determined through preclinical testing in
a canine model, higher doses may be reasonably expected to safely
produce even higher Cmax and AUC. However, 300 mg required
sequential inhalation of 12 25-mg capsules. While higher-dose
capsules are feasible, achieving the usual 15-mg/kg dose in a 70-kg
FIG 3 Graph of plasma concentration versus time for each group. The horizontal line represents an MIC of 2 g/ml for M. tuberculosis inhibition by capreo-
mycin.
FIG 4 Graphs of dose proportionality of Cmax (left) and AUC (right).
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adult (1,000 mg) may require a logistically unacceptably large
powder load and divided doses, a practice usually avoided in the
ambulatory treatment of drug-resistant tuberculosis, where full
supervision of ingestion is standard practice.
When administered parenterally as part of current MDR-TB
treatment regimens, capreomycin must be given in doses that re-
sult in very high peak serum concentrations. Although these high
Cmax concentrations inhibit mycobacterial growth, they are often
accompanied by the risk of toxicities (FDA label). Moreover, some
of these effects are potentiated when capreomycin is used concur-
rently with other nephrotoxic and ototoxic drugs, further limiting
its use. It appears that inhaled capreomycin could be a promising
option in MDR-TB management. Future studies of the pharma-
cokinetic and pharmacodynamic profiles of higher nominal doses
and multiple-daily-dosing schemes in healthy volunteers and
MDR-TB patients can help support the potential incorporation of
inhaled capreomycin into treatment regimens.
The findings of this clinical study are more significant in light
of preclinical studies of inhaled dry powder capreomycin in
guinea pigs, which highlight an important critical advantage of the
inhaled route of delivery over parenteral administration. The sys-
temic concentrations achieved after a 14.5-mg/kg inhaled dose in
the guinea pig were comparable to the systemic concentrations
seen 2 h after a 14.5-mg/kg single dose given i.v. or i.m. (24).
Furthermore, the inhaled route of delivery did not produce the
high initial spike in systemic concentrations seen within the first
hour of the i.v. or i.m. dose (24). After a single 20-mg/kg inhaled
dose, lung tissue homogenate concentrations reached 40 to 100
times the MIC for M. tuberculosis, while bronchoalveolar lavage
fluid concentrations reached 40 to 50 times the MIC (27). Eight
hours after administration of a 20-mg/kg inhaled dose, lung tissue
drug concentrations averaged 100 g/g tissue and far exceeded the
concentrations achieved by the i.m. route of administration (27).
In the multiple-dose portion of these studies, the AUC, half-life,
and lung concentrations were higher and longer-lasting after the
second and third doses (27). In addition, daily administration of
the inhaled drug over 4 weeks (at 14.5 mg/kg) resulted in signifi-
cant reductions in bacterial counts and lung pathology in M. tu-
berculosis-infected guinea pigs and the effect was greater than the
pharmacodynamic effect on bacterial counts in the lung seen with
the i.m. route of delivery of the 20-mg/kg dose (24).
Taken together, the pharmacokinetic and pharmacodynamic
data on capreomycin in guinea pigs show that the pulmonary
route of delivery of a single dose achieved systemic concentrations
above an MIC of 2 g/ml for M. tuberculosis and produced a
longer systemic half-life of the drug than that following parenteral
administration (21, 24). In humans, the systemic half-life of
capreomycin after parenteral administration has been shown to be
on the order of 2 to 3 h (28, 29). This represents only 60% of the
apparent systemic half-life observed in the current study after sin-
gle-dose pulmonary inhalation. In the guinea pig model, inhaled
drug delivery also resulted in higher concentrations in the lung
tissue and greater systemic mean residence times than when ad-
ministered parenterally (21, 27). This finding in an animal model
provides evidence that inhaled capreomycin is superior to paren-
terally administered capreomycin in terms of achieving therapeu-
tic pulmonary drug concentrations. Further clinical evaluation,
including bronchoscopy and lung lavage sampling, could be help-
ful in expanding this finding to patients. A lingering concern is the
amount of powder and number of doses needed to achieve thera-
peutic concentrations. It remains to be seen whether inhaled
capreomycin will be a practical therapeutic option in adults. Reg-
ular injections are a particular hardship for children, and the sub-
stitution of inhaled capreomycin in that population seems espe-
cially desirable and feasible. Studies done with asthmatic children
in Europe, the Americas, and Asia have shown the feasibility and
acceptability of the use of a metered dose and a dry powder inhaler
device of asthma drugs by children (30–33).
The results should also be considered in light of some of the
limitations of this study. First, subjects were predominantly male
and healthy. Second, subjects had normal pulmonary function,
but capreomycin distribution within the airways and lungs after
inhalation may be different in patients with underlying obstruc-
tive lung disease. The pharmacokinetics of inhaled capreomycin
in TB patients with or without lung disease and other comorbidi-
ties may be quite different. In some dose groups, subjects whose
TABLE 3 Pulmonary function results pre- and postdosea
Group














1 4.00  0.66 3.98  0.65 4.09  0.67 5.58  1.56 5.42  1.28 5.64  1.31 73.8  11.3 75.0  11.0 73.8  9.47
2 4.00  0.80 4.35  2.16 4.02  1.00 4.94  0.45 5.75  1.87 5.06  0.51 80.2  9.96 73.4  18.4 77.8  13.4
3 3.70  1.05 3.63  1.01 3.66  1.00 4.74  1.29 4.75  1.21 4.74  1.23 78.6  7.02 76.6  6.69 77.6  7.06
4 4.45  0.59 4.30  0.56 4.40  0.59 5.64  0.82 5.43  0.84 5.58  0.81 79.4  9.21 79.8  6.83 79.2  8.17
a Values for FEV1 and FVC are means  standard deviations for each group, in liters. Values for FEV1/FVC are percentages. Group 1, 25-mg dose; group 2, 75-mg dose; group 3,
150-mg dose; group 4, 300-mg dose.
TABLE 4 List of adverse events
Subject
Dose
(mg) Adverse event (severity)
Relationship to study
drug
001 25 Cough (mild) Related
006 75 Cough (mild) Related
008 75 Headache (mild) Probably unrelated
Chest tightness (mild) Possibly related
011 150 Cough (moderate) Related
i.v. infiltration (mild) Unrelated
012 150 Cough (moderate) Related
017 300 Cough (moderate) Related
Migraine headache (moderate) Probably unrelated
Vomiting (moderate) Probably unrelated
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half-life data did not meet inclusion criteria for analysis (as de-
scribed above) were excluded. This in turn affected the calculation
of all of the half-life-dependent PK parameters for that group.
In conclusion, the results of this first-in-human study of
inhaled capreomycin provide both a sound basis and a need for
further testing of inhaled capreomycin for therapeutic efficacy.
Given the safety profile of the doses used in this study, future
studies should evaluate higher doses of dry powder capreomy-
cin with the goal of further increasing the Cmax/MIC and AUC/
MIC ratios. The doses evaluated in the current study were be-
low the NOAEL seen in the preclinical canine model,
suggesting that testing of higher doses could be safely under-
taken. If proven efficacious, the use of dry powder capreomycin
has the potential to significantly improve the treatment of
MDR-TB by extending its ability to be administered in a wider
range of clinical settings, including in community-based treat-
ment models, in settings with limited resources, and through
self-administration under supervision. Its use in pediatric
drug-resistant tuberculosis is also attractive. Further studies to
develop and test dry powder formulations of this and other TB
drugs should be encouraged.
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